An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial

Abstract

Trastuzumab is a promising but very expensive antibody. With the current pressure on health-care budgets, cost implications of using trastuzumab in adjuvant setting must be calculated before use of the product becomes wide-spread. This provides essential information for price-setting policies and for policy makers considering reimbursement.

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

“…The magnitude of survival gain is the factor having the greatest influence on the cost-effectiveness figures. This was also concluded by Hillner [37] and Neyt and colleagues [46]. Based on the interim analysis from studies performed, a 10 Á20% improvement looks reasonable.…”

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

“…Our observation warrants larger retrospective and prospective studies aimed at strengthening these data. This would be fully justified since the introduction of trastuzumab in the adjuvant setting of breast cancer [26,27] has increased the population concerned with trastuzumab treatment, with a significant economic impact [28].…”

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial

“…So far, Neyt et al [9] conducted a cost analysis before the publication of the clinical data of the HERA trial for the Belgian health care system. They estimated combination chemotherapy with T to result in total cost of 45 000 EUR for 50 year old patients with stage III breast cancer.…”

“…Neyt et al [9] analyzed the incremental costs for health care providers, resulting from the introduction of T in adjuvant therapy in Belgium. They found an incremental cost of 45 000 Euros (EUR) per patient compared with standard regimens as doxorubicin plus cyclophosphamide or carboplatin plus docetaxel.…”